RSRoberta K. Sefcik

Roberta K. Sefcik

*This is an algorithmically generated author record based on publicly available information.

Roberta K. Sefcik has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The evolution of endovascular electroencephalography: historical perspective and future applications

    by Roberta K. Sefcik, Nicholas L. Opie, Sam E. John, Christopher P. Kellner, J Mocco, Thomas J. Oxley

    Current standard practice requires an invasive approach to the recording of electroencephalography (EEG) for epilepsy surgery, deep brain stimulation (DBS), and brain-machine interfaces (BMIs). The development of endovascular techniques offers a minimally invasive route to recording EEG from deep brain structures. This historical perspective aims to describe the technical progress in endovascular EEG by reviewing the first endovascular recordings made using a wire electrode, which was followed by the development of nanowire and catheter recordings and, finally, the most recent progress in stent-electrode recordings. The technical progress in device technology over time and the development of the ability to record chronic intravenous EEG from electrode arrays is described. Future applications for the use of endovascular EEG in the preoperative and operative management of epilepsy surgery are then discussed, followed by the possibility of the technique's future application in minimally invasive operative approaches to DBS and BMI.


  • Open Access

    Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4

    by Roberta K. Sefcik, Kian Bichoupan, ValÉRie Martel-LaferriÈRe, Joseph A. Odin, Lawrence U. Liu, Ponni Perumalswami, Meena Bansal, Douglas T. Dieterich, Jawad Ahmad, Thomas D. Schiano, et al.

    To the Editor—Benhamou et al demonstrated that the tolerability and pharmacokinetics of telaprevir in patients infected with hepatitis C virus (HCV) genotype 4 were similar to those found in HCV genotype 1 patients [1]. In their study, patients infected with HCV genotype 4 were randomly assigned to receive (1) telaprevir monotherapy for 15 days; (2) telaprevir, pegylated interferon alfa-2a, and ribavirin (TPR) for 15 days; or (3) placebo, pegylated interferon alfa-2a, and ribavirin (PR) for 15 days. After the initial 15-day treatment period, study drugs in each group were replaced with standard PR treatment, which was administered for an additional 46–48 weeks.